MedPath

Abdominal and pelvic CEST imaging: quantitative assessment of tissue function, tumor characteristic, tumor aggressiveness

Not Applicable
Conditions
ormal tissues and malignant tumors of liver, pancreas, kidney, uterus, prostate and GI
Registration Number
JPRN-UMIN000017546
Lead Sponsor
Kyushu University
Brief Summary

There was a significant difference in APTSIs between GS of 6 and GS of 7, and GS of 7 and GS of 9, but no significant differences in APTSI between GS of 6 and GS of 8, GS of 6 and GS of 9, and GS of 7 and GS of 8. The increase The APTSI in GS of 7 was the highest. The APT-MRI has a possibility as a new biomarker of Pca aggressiveness.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

Contraindication of MRI

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of CEST effects between tumor and non-tumor region. Assessment of diagnostic capability of tumor aggressiveness and histological characteristics by radiological-histological correlation.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath